Cibus Dirección

Dirección controles de criterios 1/4

Cibus' CEO is Rory Riggs, appointed in Jan 2001, has a tenure of 23.42 years. total yearly compensation is $292.31K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 14.52% of the company’s shares, worth $39.71M. The average tenure of the management team and the board of directors is 1.1 years and 1 years respectively.

Información clave

Rory Riggs

Chief Executive Officer (CEO)

US$292.3k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	23.4yrs
Participación del CEO	14.5%
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	less than a year

Actualizaciones recientes de la dirección

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Aug 17

Analysts Just Shaved Their Calyxt, Inc. (NASDAQ:CLXT) Forecasts Dramatically

May 11

Calyxt, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 08

Is Calyxt (NASDAQ:CLXT) A Risky Investment?

Apr 30

Calyxt, Inc. (NASDAQ:CLXT) Analysts Just Cut Their EPS Forecasts Substantially

Mar 09

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rory Riggs en comparación con los beneficios de Cibus?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

Compensación vs. Mercado: Rory's total compensation ($USD292.31K) is below average for companies of similar size in the US market ($USD1.55M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Rory con los resultados de la empresa.

CEO

Rory Riggs (71 yo)

23.4yrs

Permanencia

US$292,314

Compensación

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Rory Riggs	Co-Founder	23.4yrs	US$292.31k	14.52% $ 39.7m
Peter Beetham	Co-Founder	less than a year	US$292.31k	0.35% $ 962.2k
Greg Gocal	Co-Founder	8.4yrs	US$266.01k	1.49% $ 4.1m
Wade King	Chief Financial Officer	1.1yrs	sin datos	0.20% $ 538.6k
Jason Stokes	Chief Legal Officer	less than a year	sin datos	sin datos
Rosa Kim	Senior Vice President of Legal	no data	sin datos	sin datos
James Radtke	Senior Vice President of Product Development	no data	sin datos	sin datos
Tony Moran	Senior Vice President of International Development	no data	sin datos	sin datos
Norm Sissons	Senior Vice President of Seed & Traits	no data	sin datos	sin datos
Noel Sauer	Senior Vice President of Research	no data	sin datos	sin datos
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	sin datos	sin datos

1.1yrs

Permanencia media

64yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CBUS no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rory Riggs	Co-Founder	less than a year	US$292.31k	14.52% $ 39.7m
Peter Beetham	Co-Founder	less than a year	US$292.31k	0.35% $ 962.2k
Gerhard Prante	Independent Vice Chairman	less than a year	sin datos	0.33% $ 911.4k
Mark Finn	Lead Independent Director	less than a year	sin datos	0.30% $ 828.0k
Keith Walker	Independent Director	less than a year	sin datos	0.39% $ 1.1m
Joseph Ecker	Member of Scientific Advisory Board	no data	sin datos	sin datos
Jean-Pierre Lehmann	Independent Director	less than a year	sin datos	8.16% $ 22.3m
Jan Leach	Member of Scientific Advisory Board	no data	sin datos	sin datos
Stephen Howell	Member of Scientific Advisory Board	no data	sin datos	sin datos
Richard Meagher	Member of Scientific Advisory Board	no data	sin datos	sin datos

1.0yrs

Permanencia media

78yo

Promedio de edad

Junta con experiencia: CBUS's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Cibus Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

High number of new directors

Recent updates

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

Calyxt, Inc., Annual General Meeting, Jun 01, 2022

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Calyxt, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Price target increased to US$8.67

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Chief Financial Officer recently bought US$64k worth of stock

Will Calyxt (NASDAQ:CLXT) Spend Its Cash Wisely?

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.33 loss in 2Q 2020)

Calyxt, Inc.(NasdaqGM:CLXT) dropped from Russell Microcap Value Index

No longer forecast to breakeven

Independent Director recently bought US$59k worth of stock

Consensus revenue estimates fall to US$23.2m